Extending the Benefits of Targeting HER2 in Breast Cancer | Dana-Farber Cancer Institute

Nancy Lin, MD, and Paolo Tarantino, MD, discuss the outcomes of a recent study on HER2-low metastatic breast cancer from the ASCO 2022 Annual Meeting. They explain how the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) is now being used to treat HER2-low breast cancers.

[@christophersandmann]

This is an excellent presentation, even with its audio glitches. Finding detailed content on cancer is difficult on UA-cam. Thanks for being the exception.

[@oligreen1192]

Thank you

[@deetorres424]

I am her+

[@emmah37]

Same 💖

[@madmarlowe1422]

Me three. I've been her2 + metastatic going on 6 and 1/2 years

[@FiberArts22]

Me 4

[@catherinet8380]

the quality of the video is really poor--very blurry